Welcome to LookChem.com Sign In|Join Free
  • or
3,5-bis(hydroxymethyl)-1-(3-bromopropoxy)benzene is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

907625-49-4

Post Buying Request

907625-49-4 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

907625-49-4 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 907625-49-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,0,7,6,2 and 5 respectively; the second part has 2 digits, 4 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 907625-49:
(8*9)+(7*0)+(6*7)+(5*6)+(4*2)+(3*5)+(2*4)+(1*9)=184
184 % 10 = 4
So 907625-49-4 is a valid CAS Registry Number.

907625-49-4Downstream Products

907625-49-4Relevant academic research and scientific papers

Unique tetrameric and hexameric mannoside clusters prepared by click chemistry

Al-Mughaid, Hussein,Al-Zoubi, Raed M.,Paul, Nawal K.,Grindley, T. Bruce

, p. 27 - 33 (2015)

The synthesis of novel tetrameric and hexameric mannoside clusters bearing 1,2,3-trizole linkages via Cu(I)-catalyzed azide-alkyne cycloaddition reaction ("click chemistry") is described. An attractive feature of these multiarmed mannoside clusters as potential inhibitors of uropathogenic Escherichia coli is the use of an aglycone whose length is designed to fit in the tyrosine gate. The acetylated mannosides were deprotected and the corresponding de-O-acetylated mannosides were found to exhibit good water solubility.

Nitric oxide enhancing diuretic compounds, compositions and methods of use

-

Page/Page column 67, (2008/06/13)

The invention describes novel compositions and kits comprising at least one nitric oxide enhancing diuretic compound, or pharmaceutically acceptable salts thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating conditions resulting from excessive water and/or electrolyte retention; (b) treating cardiovascular diseases; (c) treating renovascular diseases; (d) treating diabetes; (e) treating diseases resulting from oxidative stress; (f) treating endothelial dysfunctions; (g) treating diseases caused by endothelial dysfunctions; (h) treating cirrhosis; (j) treating pre-eclampsia; (k) treating osteoporosis; (l) treating nephropathy; (m) treating peripheral vascular diseases; (n) treating portal hypertension; (o) treating central nervous system disorders; (p) treating metabolic syndrome; (q) treating sexual dysfunctions; and (r) hyperlipidemia. The nitric oxide enhancing diuretic compounds comprise at least one nitric oxide enhancing group linked to the diuretic compound through one or more sites such as carbon, oxygen and/or nitrogen via a bond or moiety that cannot be hydrolyzed.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 907625-49-4